About
Galleri® is a groundbreaking multi-cancer early detection (MCED) test developed by GRAIL, designed to identify cancer signals from over 50 cancer types through a single blood draw. The test works by detecting circulating cell-free DNA (cfDNA) shed by cancer cells into the bloodstream, analyzing methylation patterns to find a shared 'fingerprint' of cancer before symptoms appear. It targets many of the deadliest cancers, including types that currently lack recommended screening tests, making it a uniquely proactive health tool. Galleri is intended to be used annually alongside—not as a replacement for—existing healthcare provider-recommended screening tests. It is HSA/FSA eligible and can be ordered by patients, or offered by healthcare providers, employers, health systems, life insurers, and first responder organizations. Results are delivered through a secure online portal, and dedicated support is available for result interpretation and billing. Clinical validation comes from the PATHFINDER 2 study, which demonstrated breakthrough performance results. The test does not predict future genetic cancer risk, and false positive and false negative results can occur. Galleri is best suited for adults at elevated cancer risk who want an additional, comprehensive early-detection layer on top of standard screenings.
Key Features
- 50+ Cancer Signal Detection: Screens for signals associated with more than 50 types of cancer, including many that lack any currently recommended standard screening test.
- Single Blood Draw: All testing is performed from one simple blood sample, making the process minimally invasive and straightforward for patients.
- Cancer Signal Origin (CSO) Identification: When a cancer signal is detected, the test also predicts the tissue type or organ of origin to help guide follow-up diagnostic workup.
- Annual Screening Test: Designed to be repeated annually as a proactive, routine part of preventive healthcare alongside other recommended screenings.
- Multi-Stakeholder Access: Available through individual patient requests, healthcare provider prescriptions, employer health benefit programs, health systems, and insurance plans.
Use Cases
- Individuals seeking proactive annual cancer screening beyond standard recommended tests to detect early-stage cancers before symptoms appear.
- Healthcare providers offering comprehensive preventive care to high-risk patients by adding a multi-cancer detection layer to existing screening protocols.
- Employers and HR teams providing the Galleri test as a premium employee health benefit to improve workforce wellness and early disease intervention.
- Health systems and insurers integrating MCED testing into population health management programs to reduce late-stage cancer diagnoses.
- First responder organizations offering the Galleri test to firefighters, police, and emergency workers who face elevated occupational cancer risk.
Pros
- Broad Cancer Coverage: Detects signals for 50+ cancer types in one test, including many cancers with no existing standard screening, offering unmatched proactive coverage.
- Clinically Validated: Backed by large-scale clinical studies including the PATHFINDER 2 trial, providing evidence-based performance data for providers and patients.
- HSA/FSA Eligible: Eligible for payment via health savings or flexible spending accounts, making it more accessible for individuals with those benefit plans.
Cons
- Does Not Detect All Cancers: The test cannot detect signals for all cancer types, and not all cancers shed detectable DNA into the blood, meaning some cancers may be missed.
- Possible False Results: False positive and false negative results can occur, potentially causing unnecessary anxiety or missed diagnoses, requiring follow-up confirmatory testing.
- Paid Out-of-Pocket for Many: Insurance coverage is not universally available, meaning many patients may need to pay the full test cost themselves.
Frequently Asked Questions
What is the Galleri test?
Galleri® is a multi-cancer early detection (MCED) blood test that screens for DNA signals shed by cancer cells across 50+ cancer types, all from a single blood draw.
How does the Galleri test work?
The test analyzes cell-free DNA in the bloodstream for methylation patterns that serve as a 'fingerprint' of cancer. If a signal is detected, it also identifies the likely tissue of origin to guide further diagnostic evaluation.
Who should get the Galleri test?
The test is designed for adults, particularly those at elevated risk for cancer. It should be used in addition to—not as a replacement for—standard healthcare provider-recommended cancer screenings.
How accurate is the Galleri test?
Clinical performance has been validated through studies including PATHFINDER 2. However, false positives and false negatives can occur, and the test does not detect signals for all cancers.
Is the Galleri test covered by insurance?
Coverage varies. The test is HSA/FSA eligible (check with your plan), and GRAIL partners with some employers, health systems, and insurers, but individual insurance coverage is not guaranteed.
